Status:
COMPLETED
Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers
Lead Sponsor:
University of Cape Town
Collaborating Sponsors:
Orion Corporation, Orion Pharma
University of Oxford
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-30 years
Phase:
PHASE1
Brief Summary
The aim of the present study is to investigate changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with emotional and working memory during task performance aft...
Eligibility Criteria
Inclusion
- good command of English language
- right handedness
- normal or corrected-to-normal vision
Exclusion
- personal history or active presence of psychiatric conditions
- usage of psychotropic medication within the past 3 months
- pregnancy or breast-feeding status
- systolic blood pressure \< 90 mmHg or \> 140 mmHg at screening visit
- diastolic blood pressure \< 50 mmHg or \> 90 mmHg at screening visit
- resting heart rate \< 45 beats/minute or \> 100 beats/minute at screening visit
- active presence of medical condition at physical examination
- history of major traumatic brain injury
- any other contraindication to MRI of the brain
- use of psychoactive substances incl. alcohol in 24 hours prior to test session
Key Trial Info
Start Date :
March 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2018
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT03440021
Start Date
March 26 2018
End Date
December 6 2018
Last Update
January 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCT Dept. Psychiatry & Mental Health / CUBIC
Cape Town, Western Cape, South Africa, 7925